Abeona Therapeutics (NASDAQ:ABEO) PT Lowered to $16.00

Share on StockTwits

Abeona Therapeutics (NASDAQ:ABEO) had its price target cut by Royal Bank of Canada to $16.00 in a research report report published on Tuesday, The Fly reports. They currently have a positive rating on the biopharmaceutical company’s stock. The analysts noted that the move was a valuation call.

Other equities research analysts also recently issued reports about the stock. ValuEngine raised shares of Abeona Therapeutics from a sell rating to a hold rating in a research note on Thursday, August 1st. HC Wainwright started coverage on shares of Abeona Therapeutics in a research note on Monday. They issued a buy rating and a $15.00 price target on the stock. Zacks Investment Research raised shares of Abeona Therapeutics from a sell rating to a hold rating in a research note on Tuesday, July 30th. Maxim Group reaffirmed a buy rating on shares of Abeona Therapeutics in a research note on Wednesday, May 1st. Finally, Mizuho downgraded shares of Abeona Therapeutics from a buy rating to a neutral rating and cut their target price for the stock from $17.00 to $4.00 in a research note on Friday, July 26th. Six research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The stock currently has a consensus rating of Hold and an average price target of $19.67.

NASDAQ:ABEO opened at $2.17 on Tuesday. The company has a current ratio of 2.54, a quick ratio of 3.35 and a debt-to-equity ratio of 0.06. The company’s 50-day moving average is $3.54 and its two-hundred day moving average is $6.08. Abeona Therapeutics has a 1-year low of $2.12 and a 1-year high of $15.65.

Abeona Therapeutics (NASDAQ:ABEO) last posted its earnings results on Friday, August 9th. The biopharmaceutical company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.13). Abeona Therapeutics had a negative net margin of 960.91% and a negative return on equity of 59.99%. Equities research analysts predict that Abeona Therapeutics will post -1.74 EPS for the current year.

A number of institutional investors and hedge funds have recently made changes to their positions in ABEO. Tower Research Capital LLC TRC increased its stake in Abeona Therapeutics by 434.6% during the 2nd quarter. Tower Research Capital LLC TRC now owns 8,719 shares of the biopharmaceutical company’s stock worth $42,000 after buying an additional 7,088 shares during the period. BNP Paribas Arbitrage SA increased its stake in Abeona Therapeutics by 21,590.0% during the 1st quarter. BNP Paribas Arbitrage SA now owns 6,507 shares of the biopharmaceutical company’s stock worth $48,000 after buying an additional 6,477 shares during the period. Ellington Management Group LLC purchased a new stake in Abeona Therapeutics during the 2nd quarter worth approximately $50,000. Trexquant Investment LP purchased a new stake in Abeona Therapeutics during the 2nd quarter worth approximately $53,000. Finally, D. E. Shaw & Co. Inc. purchased a new stake in Abeona Therapeutics during the 2nd quarter worth approximately $59,000. 63.32% of the stock is currently owned by hedge funds and other institutional investors.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.

Recommended Story: What is Blockchain?

The Fly

Analyst Recommendations for Abeona Therapeutics (NASDAQ:ABEO)

Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Advanced Micro Devices  Receives New Coverage from Analysts at Loop Capital
Advanced Micro Devices Receives New Coverage from Analysts at Loop Capital
AlarmCom  Upgraded at Zacks Investment Research
AlarmCom Upgraded at Zacks Investment Research
AstroNova  Downgraded by ValuEngine
AstroNova Downgraded by ValuEngine
Valeura Energy  Receives “Buy” Rating from Canaccord Genuity
Valeura Energy Receives “Buy” Rating from Canaccord Genuity
ACM Research  Raised to Strong-Buy at Zacks Investment Research
ACM Research Raised to Strong-Buy at Zacks Investment Research
Adamas Pharmaceuticals  Upgraded at Zacks Investment Research
Adamas Pharmaceuticals Upgraded at Zacks Investment Research


© 2006-2019 Ticker Report